Radiopharm Theranostics (RADX) director holds 5.33M options at $0.06

Rhea-AI Filing Summary

Radiopharm Theranostics Ltd director Noel Donnelly has reported his initial derivative holdings in the company. He holds options to buy 5,333,333 Ordinary Shares at an exercise price of $0.0600 per share, expiring on September 30, 2029, granted on December 16, 2024.

According to the grant terms, 2,666,667 options will vest on September 30, 2026 and 2,666,666 options will vest on September 30, 2027, provided he remains a director on those dates.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Donnelly Noel

Role Director

Type	Security	Shares	Price	Value
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--

Holdings After Transaction: Option (right to buy) — 2,666,667 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options underlying shares: 5,333,333 shares Exercise price: $0.0600 per share First vesting tranche: 2,666,667 options +3 more

6 metrics

Options underlying shares 5,333,333 shares Total Ordinary Shares underlying reported options grant

Exercise price $0.0600 per share Exercise price for the reported options

First vesting tranche 2,666,667 options Options vesting on September 30, 2026

Second vesting tranche 2,666,666 options Options vesting on September 30, 2027

Expiration date September 30, 2029 Option expiration for the reported grant

Grant date December 16, 2024 Date the options were granted to Noel Donnelly

Key Terms

Option (right to buy), Ordinary Shares, exercise price, vesting, +1 more

5 terms

Option (right to buy) financial

"security_title: "Option (right to buy)""

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

exercise price financial

"exercisePrice: "0.0600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"options will vest on September 30, 2026 and September 30, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2029-09-30T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Donnelly Noel

(Last) (First) (Middle)

SUITE 1 LEVEL 3, 62 LYGON STREET

(Street)

CARLTON SOUTH, VICTORIA C3 3053

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Radiopharm Theranostics Ltd [ RADX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	09/30/2025	09/30/2029	Ordinary Shares	2,666,667	$0.06	D
Option (right to buy)	(1)	09/30/2029	Ordinary Shares	5,333,333	$0.06	D

Explanation of Responses:

1. Granted on December 16, 2024. 2,666,667 options will vest on September 30, 2026 and 2,666,666 options will vest on September 30, 2027 provided Mr. Donnelly is still a Director on such dates.

Remarks:

1. All exercise prices are in Australian dollars. 2. There are no non-derivative securities beneficially owned.

	/s/ Noel Donnelly	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What did Noel Donnelly report in his Form 3 for RADX?

He reported initial holdings of options to buy 5,333,333 Ordinary Shares of Radiopharm Theranostics at an exercise price of $0.0600 per share, expiring on September 30, 2029, reflecting his existing derivative position as a director.

What is the exercise price of Noel Donnelly’s options in Radiopharm Theranostics (RADX)?

The options reported by Noel Donnelly carry an exercise price of $0.0600 per Ordinary Share. This means he can purchase shares at that fixed price if and when the options vest and he chooses to exercise them before expiration.

How many Radiopharm Theranostics (RADX) options does Noel Donnelly hold and when do they vest?

He holds options over 5,333,333 Ordinary Shares. Of these, 2,666,667 options are scheduled to vest on September 30, 2026 and 2,666,666 options on September 30, 2027, subject to his continued service as a director.

When do Noel Donnelly’s Radiopharm Theranostics (RADX) options expire?

All the options reported in this Form 3 expire on September 30, 2029. He must exercise any vested options before that expiration date; otherwise, the right to purchase shares at $0.0600 per share will lapse.

Were Noel Donnelly’s Radiopharm Theranostics (RADX) options recently granted?

Yes. The footnote explains these options were granted on December 16, 2024. The grant includes two vesting tranches in 2026 and 2027, conditional on Noel Donnelly continuing to serve as a director through those vesting dates.